- Conditions
- Stroke, Hemiplegia, Cerebrovascular Accident (CVA), Hemiparesis
- Interventions
- Contralaterally Controlled Functional Electrical Stimulation, New rTMS approach, Conventional rTMS approach, Sham rTMS approach
- Device
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection, Interleukin
- Interventions
- FT538, Vorinostat
- Biological · Drug
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Amputation, Diabetes Mellitus, Peripheral Artery Disease
- Interventions
- Walking Biobehavioral Intervention, Attention Control
- Behavioral · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Chronic Pain
- Interventions
- Hydrocodone
- Drug
- Lead sponsor
- NEMA Research, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Naples, Florida • Leawood, Kansas
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin detemir
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 66
- States / cities
- Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab 162 mg, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 656 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Contraception, Inhalation of Nitrous Oxide
- Interventions
- In-office Transcervical Sterilization (Essure®), Standard Oral pain medications, Intramuscular Ketorolac, Placebo pills, Oxygen, Nitrous Oxide
- Procedure · Drug · Other
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Language Delay, Language Development, Feeding; Difficult, Newborn, Mother-Infant Interaction, Maternal Behavior
- Interventions
- Oromotor stimulation, Reading curriculum, LENA recording, LENA linguistic feedback, No oromotor stimulation
- Behavioral
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 23 Weeks to 30 Weeks
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Acute Myeloid Leukemia
- Interventions
- AZD1152, LDAC
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Chicago, Illinois • New York, New York + 5 more
- Conditions
- Cancer
- Interventions
- GSK1120212 plus everolimus
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • San Antonio, Texas
- Conditions
- Alveolar Ridge Deficiency
- Interventions
- Xenograft and allograft
- Device
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Primary Insomnia
- Interventions
- Cognitive Behavior Therapy-Insomnia, Focus of Attention, Combined-CBT-I and FOA Group, Sleep Hygiene
- Behavioral
- Lead sponsor
- Pacific Institute of Medical Sciences
- Other
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Bothell, Washington
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
- Interventions
- bortezomib, filgrastim, autologous hematopoietic stem cell transplantation
- Drug · Biological · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Meningococcal Infections, Meningitis
- Interventions
- Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- East Stroudsburg, Pennsylvania
- Conditions
- Rheumatoid Arthritis
- Interventions
- Golimumab, Methotrexate, Placebo
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 20
- States / cities
- Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
- Conditions
- Opioid Use Disorder
- Interventions
- Ketamine, Mindfulness-Oriented Recovery Enhancement (MORE), Support Group
- Drug · Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • Salt Lake City, Utah
- Conditions
- Healthy
- Interventions
- Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg, Odalasvir 75 mg, AL-335 800 mg, Lansoprazole 30 mg, Omeprazole 20 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Thromboembolism
- Interventions
- IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment
- Genetic · Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Anxiety, COVID-19 Pandemic
- Interventions
- Mindfulness
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Velacur, MRI, Blood sample collection for biomarkers, Liver biopsy
- Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Lymphedema
- Interventions
- Exercise Intervention, Weight Loss Intervention
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- Up to 80 Years · Female only
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- BK Virus Infection, BK Virus Nephropathy
- Interventions
- New Protocol - BK viremia or BK virus nephropathy, Standard Protocol - BK viremia or BK virus nephropathy
- Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab, Tarceva, Temozolomide
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cancer, Lentigo Maligna
- Interventions
- Imiquimod Cream, Tazarotene Cream 0.1%
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah